Abstract

Purpose of Review  Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune/inflammatory disease that results in significant damage and disability. When compared to patients with disease onset in adulthood, jSLE patients exhibit increased disease activity, damage and require more aggressive treatments. This manuscript summarises age-specific pathogenic mechanisms and underscores the need for age group–specific research, classification and treatment.

Recent Findings  Genetic factors play a significant role in the pathophysiology of jSLE, as > 7% of patients develop disease as a result of single gene mutations. Remaining patients carry genetic variants that are necessary for disease development, but require additional factors. Increased ‘genetic impact’ likely contributes to earlier disease onset and more severe phenotypes. Epigenetic events have only recently started to be addressed in jSLE, and add to the list of pathogenic mechanisms that may serve as biomarkers and/or treatment targets. To allow meaningful and patient-oriented paediatric research, age-specific classification criteria and treatment targets require to be defined as currently available tools established for adult-onset SLE have limitations in the paediatric cohort.

Summary  Significant progress has been made in understanding the pathophysiology of jSLE. Meaningful laboratory and clinical research can only be performed using age group–specific tools, classification criteria and treatment targets.

Keywords  Juvenile onset · Childhood · Systemic lupus erythematosus · Genetics · Epigenetics · Pathophysiology · Treatment · Classification

Abbreviations

ACR  American College of Rheumatology
ALPS  Autoimmune lymphoproliferative syndrome
ANA  Anti-nuclear antibodies
anti-dsDNA  Anti-double-stranded DNA antibodies
BLYS  B Lymphocyte Stimulator
CD70  TNFSF7-tumour necrosis factor ligand superfamily member 7
CNV  Copy number variation
CREMα  cAMP response element modulator α
DNase1  Deoxyribonuclease 1
DNASE1L3  Deoxyribonuclease 1 like 3
DNMTs  DNA methyl-transferases
DUSP4  Dual specificity protein phosphatase 4
EULAR  European League Against Rheumatism
EULAR  European League Against Rheumatism
FAS  Fas cell surface death receptor
FASL  Fas ligand
FCRL3  Fc receptor like 3
GRS  Genetic Risk Score
GTI  Glucocorticoid Toxicity Index
GWAS  Genome-wide association studies
HDACi  HDAC inhibitor
HDACs  Histone deacetylases
HRQOL  Health-related quality of life
IFN  Interferon
IL-2  Interleukin-2
jSLE  Juvenile-onset systemic lupus erythematosus

Juvenile-onset systemic lupus erythematosus (jSLE) is a rare but severe multisystem autoimmune/inflammatory disease that can affect any organ system and cause significant damage, disability and/or death. It is defined by disease onset before the age of 18 and affects approximately 15–20% of SLE patients [1–5]. The incidences of jSLE ranges between 0.36 and 2.5 per 100,000 children, with a prevalence of 1.89–34.1 per 100,000 [6–10]. Compared to adult-onset SLE, jSLE is more aggressive, with higher disease activity and medication burden (including corticosteroids and other immunosuppressive drugs) that contributes to the increased morbidity and mortality associated with the disease [1, 11, 12], more severe organ manifestations, the presence of greater damage at the time of diagnosis, and a higher incidence of renal, cardiovascular and neuropsychiatric involvement [1, 12–14]. Overall standardised mortality rates are higher in jSLE when compared to the general population (SMR 2.2 across all ages), and in patients under the age of 18 in particular, the SMR is approximately three times higher than normal (SMR 6.5) [15]. Diagnosis and treatment of jSLE can be difficult and is complicated by marked heterogeneity between individual jSLE patients in terms of disease presentation and progression, treatment response, and in their overall disease severity with some experiencing mild disease and others having life-threatening manifestations [16].

Here, we will discuss age-related factors contributing to the clinical phenotype and disease progression in jSLE, including genetic and epigenetic alterations; we will summarise new developments in patient stratification and treatment options, and touch on future research directions and initiatives to improve quality of life and outcomes in jSLE.

Impact of Age on Disease Presentation The peak age of jSLE onset is 12.6 years [16]. Patients with very early disease onset (before 5 years of age) are more likely to display an atypical presentation (e.g. lack of autoantibodies), more severe disease courses and poor prognosis [2, 15, 17–19]. A recent study involving 418 jSLE patients from the UK showed that, at diagnosis, adolescent jSLE patients (14–18 years) presented with a higher number of American College of Rheumatology (ACR) 1997 classification criteria when compared to pre-pubertal (≤ 7 years) and peri-pubertal patients (8–13 years), with higher levels of mucocutaneous, musculoskeletal, renal and cardiorespiratory disease activity (all p < 0.05). Adolescent jSLE patients (> 13 years) also differed from younger age groups (peri-pubertal, 8–13 years; pre-pubertal, < 8 years) in terms of serological disease patterns, displaying more frequent ANA positivity and higher anti-dsDNA titres (both p < 0.05). The youngest patient group less frequently presented with leukopenia (p = 0.002), thrombocytopenia (p = 0.004) and/or low complement (p = 0.002) when compared to older age groups. The present study supports the hypothesis that patients diagnosed with jSLE during adolescence may display a more ‘classic’ SLE phenotype due to variation in the pathogenic mechanisms at different ages, accounting for the more atypical SLE presentation seen in younger patients [20].

Ethnic Differences, Disease Presentation and Course Studies in adult-onset SLE cohorts have demonstrated that ethnicity has a strong impact on disease course and outcomes [10, 21–28]. A very recent study from the UK has similarly confirmed this to be the case in jSLE, with Black African/Caribbean jSLE patients showing more ‘classical’ laboratory and clinical features when compared to White Caucasian or Asian patients at diagnosis. The study also showed that Black African/Caribbean jSLE patients exhibit more renal involvement and more frequently receive cyclophosphamide and rituximab during their disease course when compared to patients of other ethnicities. Similar to adult studies, jSLE was found to be more prevalent in patients from minority ethnic backgrounds, compared to the UK national census figures for prevalence of ethnic minorities in the population as a whole, with 51% of UK jSLE Cohort Study participants being

**LINE-1** Long interspersed nuclear element-1
**miRNAs** Micro-RNAs
**PBMC** Peripheral blood mononuclear cell
**PedsQL** Paediatric Quality of Life inventory
**PKCD** Protein kinase C delta
**PP2AC** Protein phosphatase(PP)2Ac
**PRINTO/ACR** Paediatric Rheumatology International Trials Organisation/American College of Rheumatology
**RCT** Randomised controlled trial
**RR** Relative risk
**SLEDAI** Systemic Lupus Erythematosus Disease Activity Index
**SLICC** Systemic Lupus International Collaborating Clinics
**SMR** Standardized mortality rates
**SNPs** Single-nucleotide polymorphism
**SRI4** SLE responder index 4
**T2T** Treat to target
**TARGET LUPUS** Targeting disease, Agreeing Recommendations and reducing Glucocorticoids through Effective Treatment in LUPUS
**TLR** Toll-like receptor
**TREX1** Three prime repair exonuclease 1
**TSA** Trichostatin A
Genetic Factors

Genetic mutations or polymorphism, aneuploidy (abnormal number of chromosomes) and copy number variations are events that can cause or contribute to disease, while allowing for phenotypic variation in human population and (at least partially) explain complex inheritance.

Gene Mutations and Monogenic Disease As briefly mentioned above, familial clustering of SLE patients, (relatively) high disease concordance in monzygotic twins (40–60%), and increased risk and poor prognosis of individuals of African or Asian descent suggest that genetic factors play a critical role in the pathogenesis of SLE [5, 33]. However, especially based on the observation that disease penetrance is limited (e.g. concordance rates in genetically identical twins), SLE has been identified as a pathophysiologically highly complex condition in which gene mutations, polymorphisms and additional factors may be involved.

Indeed, only a relatively small number of patients diagnosed with SLE (estimated 1–4% across all age groups) carry highly penetrant mutations in single genes that are strong enough to cause disease. So-called monogenic SLE is caused by mutations in genes involved in the complement pathway, nucleic acid sensing and processing, apoptosis, and/or lymphocyte activation [2].

While the exact molecular pathophysiology is not known for all, mutations affecting the early the complement pathway (C1q, C1r, C1s, C2, C4A and C4B) [34-39] result in inflammation and immune activation through incompletely understood mechanisms. Defective clearance of immune complexes results in their deposition in peripheral tissues, local inflammation, cytokine expression (including type I interferons) and immune cell infiltration which amplifies the above. Another mechanism may be the altered negative selection of self-reactive B lymphocytes in complement C4 deficiency. Indeed, insufficient clearance of cellular debris, which is dependent on complement activation, is a key mechanism not only in primary complement deficiencies but also in more common ‘classical’ forms of SLE [2, 4, 30, 40]. Recently, a genome-wide analysis on a large British-French jSLE cohort investigated rare mono-allelic variants, further highlighting the importance of the complement pathway [41•].

Disturbed apoptosis may be involved in SLE and other autoimmune/inflammatory conditions, and mutations in the FAS (Fas cell surface death receptor) or FASL (Fas ligand) [42, 43] genes, regulators of activation-induced cell death, result in autoimmune lymphoproliferative syndrome (ALPS). Mice deficient of Fas (MRL.Lpr mice) are prone to SLE-like disease and generalised lymphoproliferation. In both humans with gene mutations and genetically modified mice, ineffective elimination of T lymphocytes results in lupus-like disease, systemic inflammation, and tissue and organ damage [2, 4, 30, 40, 44, 45].

A number of genes affecting nucleic acid metabolism and sensing have been linked with increased type I interferon expression, the resulting presence of a so-called interferon signature, systemic inflammation and clinical pictures that (more or less) resemble SLE [2, 4, 40]. Impaired processing and removal of chromatin components (including DNA) contribute to autoantibody production and tissue damage (as also happens in aforementioned complement deficiencies). In humans and mice deficient in DNase1, accumulation of extracellular chromatin contributes to immune activation, type I interferon expression, autoantibody production and subsequently lupus-like disease. Rare familial cases of SLE segregate with autosomal recessive mutations in DNase1 (deoxyribonuclease 1) or DNASE1L3 (deoxyribonuclease 1 like 3, a homologue of DNase1), extracellular accumulation of DNA, autoantibody production, complement consumption and early-onset SLE [44, 45]. Loss-of-function mutations in the gene encoding for the repair exonuclease TREX1 (three prime repair exonuclease 1) result in uncontrolled type I interferon expression and the clinical phenotype described as familial chilblain lupus that is characterised by painful and sometimes ulcerating chilblain lesions. Loss of TREX1 results in cytoplasmic accumulation of single-stranded DNA, which is detected by the nucleic acid sensing machinery resulting in type I interferon release. Thus, DNASE1, DNASE1L3 and TREX1 mutations are key representatives of primary type I interferonopathies, some of which share clinical characteristics with SLE [2, 4].
All of the aforementioned (and additional) monogenic SLE-like diseases following Mendelian inheritance are usually characterised by disturbed apoptosis, with mutations in the FAS (Fas cell surface death receptor) or FASL (Fas ligand) [42, 43] genes, regulators of activation-induced cell death, resulting in autoimmune lymphoproliferative syndrome (ALPS). Mice deficient of Fas (MRL/lpr mice) are prone to SLE-like disease and generalised lymphoproliferation. In both humans with gene mutations and genetically modified mice, ineffective elimination of T lymphocytes results in lupus-like disease, systemic inflammation, and tissue and organ damage [2, 4, 30, 40, 44, 45].

Relatively recently discovered and explored mutations in PKCD (protein kinase C delta), which plays a role in cell apoptosis and proliferation, but is also involved in B-cell negative selection, segregate with SLE-like disease likely affecting the same or closely related pathways as the above [46–49].

Taken together, rare gene mutations affecting innate or adaptive immune signalling can result in SLE-like clinical phenotypes. Genetic forms of SLE/SLE-like disease may be over-represented in patients with ‘early-onset SLE’, which is characterised by disease expression within the first years of life [19]. Characteristically, early-onset SLE patients present with severe and sometimes ‘not classical’ symptoms of SLE (such as lack of autoantibodies), and can show poor response to routine treatment [2, 5, 19, 40]. In addition to aforementioned genes, genome-wide association studies (GWAS) and targeted approaches have revealed associations between mutations in one of more than 40 genes and monogenic SLE-like conditions [2, 4].

**Gene Polymorphisms and Risk Alleles** As mentioned above, only few patients diagnosed with SLE carry disease-causing mutations in single genes. Most individuals have a genetically determined risk for the development of SLE (e.g. disease-associated risk alleles) that requires additional factors to be present or accumulate over time to result in clinical disease [2, 4, 5, 40]. Genome-wide association studies (GWAS) and targeted approaches, conducted mainly in adult-onset SLE cohorts, have revealed associations between polymorphisms in multiple genes, some of which are involved in B- and/or T-cell activation, neutrophil and monocyte biology, TLR (Toll-like receptor) and interferon signalling, inflammation, immune complex processing and cell clearance [50]. Some of these variants were assessed and confirmed in jSLE cohorts and associations were identified with some patient-disease characteristics (summarized in Table 1).

**Ancestry-Specific Genetic Polymorphisms and Disease Susceptibility** As mentioned above, SLE patients of different ethnic backgrounds exhibit significant differences in clinical disease presentation, treatment response and disease course [2, 4, 5]. These clinical observations are underpinned by several known genetic associations.

In contrast to Caucasian and Asian populations, the rs2304256, rs280500 and rs12720270 variants in TYK2 are not associated with jSLE in Mexican populations. Moreover, rs12720356 and rs34536443 variants have a lower frequency in Mestizos as compared to ‘Spaniards’ and are absent or rare in indigenous populations, suggesting that the presence of these alleles in the entire Mexican population was introduced by Spaniards. Thus, the authors claim that Mexican Mestizos may have inherited higher frequencies of SLE risk alleles from the indigenous population, while protective variants may have been subject to negative selection [72]. In the same Mestizo (person of combined European and Indigenous American descent) population, Ramirez-Bello et al. did not observe associations between FCRL3 (Fc receptor like 3) variants and jSLE, while associations exist in European and some Asian populations [73]. In a recent paper, Webber et al. described an association between several SLE risk alleles and lupus nephritis risk in children with a European background [55].

A better understanding of the contribution of ethnicity-related genetic risk, clinical presentations and associated outcomes will improve the understanding of disease pathophysiology, allow for patient stratification and individualised treatment, as well as outcome assessment.

**The Contribution of Risk Alleles to Early Disease Onset in SLE** As children and young people with jSLE, in the absence (or at least with fewer) of comorbidities and environmental impacts accumulated, exhibit more severe clinical phenotypes and reduced response to standard treatment when compared to adult-onset SLE patients, increased genetic risk is likely contributing. Approximately 7–8% of children [41] (unpublished data from the UK jSLE cohort study) exhibit monogenic disease that classifies as SLE. This percentage is higher as compared to the overall SLE population across age groups (estimated 1–4%), but only explains a relatively small fraction of cases [2, 5]. Thus, an increased number of risk alleles have been proposed contributing to jSLE.

Webb et al. reported an increased number of SLE-associated polymorphisms in jSLE patients when compared to Gullah and African-American adult-onset SLE patients. The authors therefore concluded that genetic risk has a key role in determining age of disease onset in SLE patients with SLE of African descent, which is also an important predictor of disease severity [74]. Similarly, Joo et al. calculated Genetic Risk Scores (GRS) in a Korean cohort and demonstrated that jSLE is associated with a higher GRS when compared to adult-onset SLE [75]. Lastly, in a recent study, Webber et al. observed that effect of both non-HLA and HLA GRS for the development of lupus nephritis were higher in patients with juvenile- as compared to adult-onset SLE. However, differences did not reach statistical significance [55]. Moreover, some variants were distinct between juvenile- and adult-onset SLE (Table 2).
| Gene       | Variant                              | Pathways involved              | Description                                                                 | Ethnicity/origin | References |
|------------|--------------------------------------|--------------------------------|------------------------------------------------------------------------------|------------------|------------|
| C1q        | rs292001                             | Immune complex clearance       | Mutation associated with lupus nephritis development                         | Egyptian         | [51]       |
| ETS1       | rs4937333                            | Immune cell signalling          | Mutation associated with proteinuria                                          | Japanese         | [52]       |
| HLA-DRB1   | HLA-DRB1*15 (15 g) allele            | B and T cells signalling        | Risk factor for SLE                                                            | Egyptian         | [53]       |
|            | HLA-DRB1*17, HLA-DRB1*10, HLA-DRB1*15 and HLA-DRB1*07 alleles |                                | Contribution of HLA-DRB1 alleles related to renal histologic classes, especially class I, class II A, class II B and class V | Brazilian        | [54]       |
| IFIH1      | rs2111485                            | TLR/IFN signalling              | Lupus nephritis-protective effect                                             | Multi-ethnic cohort | [55]       |
| IL1β       | rs16944                              | Immune cell signalling          | Risk factor                                                                  | Iranian           | [56]       |
| IL10       | rs1800871, rs1800872                 | Immune cell signalling          | Increase the susceptibility to nephritis for GCC haplotype                   | Thai              | [57]       |
| IL1B       | rs1143629                            | Immune cell signalling          | Disease development                                                            | Brazilian         | [58]       |
| IL17A      | rs2275913, rs763780, rs2397084        | Immune cell signalling          | Risk factor                                                                  | Egyptian         | [59]       |
| IRAK1      | rs10127175                           | TLR/IFN signalling              | Risk factor                                                                  | Multi-ethnic cohort | [60]       |
|            | rs2239673, rs763737, rs5945174, rs7061789 |                                | 4 SNP haplotypes (GGGG) being strongly associated with the disease in 3 (African Americans, Asian Americans and Hispanic Americans) of 4 different ethnic groups (not on European American) | Multi-ethnic cohort | [61]       |
| IRF5       | rs2004640, rs10954213, rs2004640, rs2280714 rs729302, rs11768806, rs4728142,rs3807135, rs2004640, rs752637,rs3807306, rs2280714 | TLR/IFN signalling              | rs2004640 increases risk of nephritis development                           | Egyptian         | [62]       |
|            |                                      |                                | Risk factor                                                                  | Multi-ethnic cohort | [63]       |
| JAZ1F      | rs10245867                           |                                | Risk factor                                                                  | Multi-ethnic cohort | [55]       |
| MBL2       | rs7096206                            | Complement pathway              | Higher risk of cutaneous manifestations and pleuritis/pericarditis           | Hungarian         | [64]       |
| NRF2       | 653G/A                               | Oxidative stress                | Nephritis in childhood onset female SLE patients                             | Mexican           | [65]       |
| PTPN22     | rs2476601                            | Immune cell signalling          | Risk factor                                                                  | Mexican           | [66]       |
| SELP       | rs3917815                            | Immune cell signalling          | Risk factor                                                                  | Multi-ethnic cohort | [67]       |
| SSP1       | rs9138                               | TLR signalling                  | Association with proteinuria                                                  | Japanese          | [52]       |
| STAT1      | c862A>G; p.T288A                      | Immune cell signalling          | Risk factor                                                                  | –                 | [68]       |
| STAT4      | rs7582694                            | Immune cell signalling          | Disease manifestation (malar rash, photosensitivity, hair falling, increase 24 h protein in urine, ANA+, dsDNA and anti-Sm detection and decreased of C3 and C4) and higher SLEAI and damage index | Egyptian         | [69]       |
|            | rs7574865                            |                                | Association with malar rash                                                  | Japanese          | [52]       |
| TNFAIP3    | rs2230926                            | NF-κB signalling                | Associated with SLE in male subgroup                                          | Japanese          | [52]       |
| TNF        | 308-A                                | Immune cell signalling          | Risk factor                                                                  | Mexican           | [70]       |
|            | 863C>A                               |                                | Nephritis and Raynaud phenomenon                                              | Iranian           | [71]       |
| UBE2L3     | rs131658                             | NF-κB signalling                | Association with lupus nephritis                                             | Multi-ethnic cohort | [55]       |
Aneuploidy as a Genetic Risk Factor for SLE

Aneuploidy is defined as an abnormal number of (entire or parts of) chromosomes in a cell, tissue or entire organism due to abnormal meiosis [81].

The X chromosome contains a number of genes involved in the regulation of innate and adaptive immune responses, including TLR7, TLR8, IRAK1, IL2RG, FOXP3 and CD40L. Studies targeting sex-related differences of immune responses investigated effects mediated by the number of X chromosomes and delivered an increased risk for the development of SLE with growing numbers of X chromosomes.

In males (physiologically having one X and one Y chromosome), the presence of an additional X chromosome, such as 46, XX in la Chapelle’s syndrome or 47, XXY in Klinefelter’s syndrome, is associated with an increased risk of SLE. This risk is similar to euploid women (46, XX); and no differences in SLE disease phenotypes between aneuploid men with an additional X chromosome and euploid women were observed [82, 83]. The prevalence of SLE in males with Klinefelter’s syndrome is nearly 14-fold higher when compared to boys/men with 46, XY karyotypes [84]. In 2016, Liu et al. reported an increased prevalence (~2.5 times higher than in women 46, XX and ~25 times higher than in men 46, XY) of SLE in a cohort of females with an additional X chromosome (47, XXX karyotype) [85]. Conversely, the prevalence of SLE in females with Turner’s syndrome (45, X0 karyotype) is lower when compared to women with 46, XX karyotypes [83]. Recently, Webb et al. reported that the presence of two X chromosomes, independent of serum sex hormones, may be responsible for increased production of type 1 interferons by plasmacytoid dendritic cell as a result of TLR7 stimulation, which may centrally contribute to the increased prevalence of SLE in females [86]. However, additional laboratory investigation is needed to sufficiently understand the involvement of X chromosomes and X chromosome gene dose effects in SLE.

In addition to aneuploidy of the X chromosome, also aneuploidy and mosaicism of chromosome 9 has been reported in SLE patients. Zuang et al. described a familial cluster of SLE patients with a chromosomal translocation involving chromosome 9. The authors concluded that patients’ autoimmune phenomena relate to having three copies of the type 1

| Gene    | Variant | Pathway involved          | Description                                                                 | Ethnicity  | References |
|---------|---------|---------------------------|-----------------------------------------------------------------------------|------------|------------|
| ESR1 and ESR2 | rs2234693, rs4986938 | Oestrogen-related pathways | Two distinct associations, an association between ESR1 polymorphism and JSLE, and between ESR2 and aSLE | Polish     | [76]       |
| ORα     | Polymorphism | Oestrogen-related pathways | Association with age at disease onset                                         | Korean     | [77]       |
| MBL2    | rs7096206 | Complement pathways       | Could be strongly associated with juvenile onset of SLE and also related to specific organ involvement | Hungarian  | [64]       |
| STAT4   | rs7574865, rs7601754 | Immune cell signalling     | Lack of association with susceptibility to JSLE in Iranian population, despite their association with the risk of adult SLE in the same population | Iranian    | [78]       |
| MECP2   | rs1734787, rs1734791 | Chromatin regulation      | SLE susceptibility variants in Iranian population. However, none of them was associated with JSLE risk | Iranian    | [79]       |
| PDCD1   | PD1.3A  | T-cell signalling, NF-κB signalling, adaptive immune system | Weaker association of this SNP with childhood-onset SLE female patients compared with that reported by Prokunina et al, in Mexican female adults with SLE | Mexican    | [80]       |
IFN (Interferon) cluster located on the p (short) arm of chromosome 9, as they also observed increased IFN-α/β and IFN receptor signalling in patients [87]. A mosaic tetrasomy affecting a 42-Mb spanning region on chromosome 9p24.3q12 was observed in a 6-year-old girl with myositis and lupus-like features. This 42-Mb region includes 495 genes, among them 26 encoding for interferon (IFN) pathway related genes [88]. Overall, these reports support the hypothesis that abnormal regulation of type I IFN production is involved in the pathogenesis of SLE, especially in children.

Increased DNA damage and genomic instability are possible outcomes of chromosome gain that can trigger inflammation and result in SLE-like phenotypes. The exact underlying mechanisms, however, remain to be addressed in future studies [81].

Copy Number Variation Copy number variation (CNV) is caused by the loss or gain of genomic segments. Classically, CNVs are defined as events that affect genomic regions longer than 1 kb. It can be observed in healthy individuals, but has ‘gene dose’ effects affecting susceptibility and outcomes in autoimmune disease and beyond. CNV is common across healthy populations with allelic properties similar to aforementioned SNPs (single-nucleotide polymorphisms). A recent study highlights that both rare and common CNVs can have a biological impact in health and disease [89].

Low total C4, C4A and C4B gene copy numbers are associated with an increased risk for the development of jSLE and associated pericarditis (low total C4, C4A) [90].

In Mexican populations, increased copy numbers of TLR7 are a susceptibility factor for jSLE, which especially affects male patients, providing additional evidence for the role of X-linked gene dose effects in SLE [91].

As highlighted by Bueno Barbosa et al. in their study on adult-onset SLE, evaluation of the fine-scale architecture of CNV regions, as well as the prediction of pathogenicity of long segments encompassing several homozygous variants found, will contribute to understanding how risk loci harbouring CNV segments affect the aetiology and pathology of SLE [92].

Altogether, the identification of single-nucleotide polymorphism as well as larger extended haplotypes that may include aneuploidy and/or copy number variation will result in a better understanding of pathomechanisms in SLE and resulting disease phenotypes.

Epigenetic Factors

Genetic variation affects the risk for SLE across ages. However, with the exception of rare monogenic SLE-like conditions, gene variants associated with SLE are not strong enough to confer disease, and additional factors must be accumulated over time to cause disease in a genetically predisposed individual [2, 5, 32, 40]. Epigenetic mechanisms impact upon DNA accessibility and gene transcription without affecting the underlying gene sequence itself. Three main groups of epigenetic mechanisms are currently investigated including DNA methylation, posttranslational histones modifications and non-coding RNAs. Together (and/or individually), these mechanisms regulate DNA compaction and accessibility. Dysregulation of epigenetic events has been linked with a host of health conditions, including cancer and autoimmune disease. However, data from paediatric patient cohorts (including jSLE) are limited.

DNA Methylation DNA methylation is a stable, heritable but also reversible epigenetic mark. During de novo methylation or after cell division, DNA methylation is mediated through the covalent transfer of a methyl group to the fifth carbon position of the cytosine pyrimidine ring by DNA methyltransferases (DNMTs). Usually, DNA methylation happens at CpG dinucleotides. DNA methylation is involved in cell differentiation, transposable element silencing and imprinting of genes. Its dysregulation has been linked with carcinogenesis, autoimmune/inflammatory disease and other diseases [93, 94].

In adult-onset JSLE, hypomethylation of CD70 (encoding for TNFSF7-tumour necrosis factor ligand superfamily member 7) in CD4+ T cells results in increased gene expression and subsequently enhanced B-cell stimulation that contributes to the pathogenesis of SLE [95–98]. Findings may be specific to CD4+ T cells, as Keshavarz-Fathi et al. did not observe statistically significant differences in CD70 promoter methylation of peripheral blood mononuclear cells (PBMCs) from patients with jSLE [99].

Long interspersed nuclear element-1 (LINE-1) are repetitive DNA elements that represent about 21% of the human genome and is often used as a marker of global DNA methylation [100]. In LINE-1 DNA methylation in PBMCs from jSLE patients, Huang et al. observed a significant correlation between disease activity and DNA hypomethylation, mainly in patients with mild to severe disease activity (based on SLEDAI (Systemic Lupus Erythematosus Disease Activity Index)-2000) indicating that hypomethylation may reflect disease. Furthermore, LINE-1 methylation levels were lower in jSLE than SLE and negatively correlated to homocysteine concentration, which is higher in this patient group. Their findings support the idea that disruption of one-carbon unit metabolism and hypomethylation of LINE-1 occur in jSLE [101].

Unfortunately, data on molecular events mediating alterations in jSLE are limited and does (to our knowledge) not include studies investigating global DNA methylation. However, Hofmann et al. [102] determined increased expression of the transcription factor cAMP response element modulator α (CREMx) in CD4+ T cells from patients with jSLE.
This is in line with observations in adult-onset disease, where CREMα has been established as a key driver of epigenetic dysregulation (including DNA methylation) through its interactions with DNMTs, among others, resulting in silencing of the IL2 gene [31, 103–106], a hallmark of effector T cells in SLE.

**Posttranslational Histone Modifications** Histones are small, arginine- and lysine-rich proteins, organised in octamers that build complexes with segments of 147 base pairs of genomic DNA that are then referred to as nucleosomes. The N-terminal part of histones (‘tail’) is accessible to posttranslational modifications (methylation of arginine or lysine residues, acetylation, ubiquitylation and SUMOylation of lysine and phosphorylation of serine or threonine groups), which modulate DNA compaction and accessibility. They act sequentially or in combination and define the ‘histone code’ [32, 98, 107]. This code can be read and interpreted by other different families of enzymes, including lysine acetyltransferases, HDACs (histone deacetylases), lysine methyltransferases and lysine demethylases, sensitive to these changes, capable of linking chromatin and reshape its organisation, thus regulating processes such as transcription, DNA replication and repair [108]. Alterations to the histone code are involved in the pathophysiology of autoimmune/inflammatory disorders [32, 98, 107].

In PBMCs from patients with jSLE, mRNA expression of IRF5, IFN-α and Sp1 is increased. Exposure of cells to HDAC (histone deacetylase) inhibitor TSA (trichostatin A) or forced histone acetylase p300 expression repressed IRF5 promoter activity, suggesting the use of HDACi (HDAC inhibitor) as a potential future therapeutic option in SLE [109].

As mentioned above, recently, Hofmann et al. linked dysregulation of the CREMα (cAMP response element modulator α)/DUSP4 (dual specificity protein phosphatase (DUSP) 4) axis in CD4+ T cells from jSLE patients with effector cytokine expression [102•]. As in adult-onset SLE, the transcription factor CREMα is expressed at increased levels in CD4+ T cells from jSLE patients as compared to matched controls [102•, 103, 106]. In CD4+ T cells from jSLE patients, CREMα induces DUSP4 (dual specificity protein phosphatase 4A) expression through co-recruitment of the transcriptional coactivator p300 that mediates histone acetylation. Increased histone acetylation at DUSP4 promotes gene expression, subsequently resulting in reduced phosphorylation of the transcription factor STAT5 which in turn mediates increased IL-17A and limited IL-2 expression, a hallmark of SLE-associated effector T-cell phenotypes [102•]. These observations are in line with a number of studies in adult-onset SLE patients linking CREMα overexpression with altered epigenetic marks (DNA methylation and histone modifications) that affect effector cytokine expression [31, 32, 103, 105, 106, 110–112].

**Non-coding RNAs** Micro-RNAs (miRNAs) are the most widely studied non-coding RNAs. They are small RNA molecules that contain 18–25 nucleotides and control mRNA stability and integrity, thereby fine-tuning between 30 and 80% of human genes [113]. Altered miRNA expression play crucial roles in a variety of pathological processes [114], including autoimmune/inflammatory disease.

Preliminary evidence also links miRNAs with the pathophysiology of jSLE. Lashine et al. identified reduced expression of mir-155 in PBMCs from jSLE patients. MiR-155 is involved in PP2AC (protein phosphatase(PP)2Ac) expression, a regulator of IL-2 (interleukin-2) release that has been implicated in the pathophysiology of SLE [115–120]. Downregulation of miR-155 is inversely correlated with SLEDAI scores and proteinuria, and positively correlated with blood leukocyte counts [121]. Thus, delivery of mir-155 may be a potential future therapeutic intervention in SLE to rescue IL-2 expression.

Taken together, epigenetic alterations can be acquired through exposure to the environment. Altered epigenetic marks can contribute to disease expression in individuals genetically predisposed to disease development. Understanding the exact causes and molecular effects of epigenetic alterations will aid in biomarker identification and the prevention and/or treatment of jSLE.

**Treatment, Targets and Trials**

**What Is New in Treatment of jSLE?** Due in large to jSLE being a relatively rare disease, treatment paradigms are often extrapolated from adult SLE. Sufficiently powered randomised controlled trials (RCTs) in jSLE are scarce. Most available treatment options are not targeted, and can cause significant adverse events and toxicity [2, 4], particularly in vulnerable age groups such as children and young people.

Although ‘new’ biologic therapies are used for many autoimmune conditions, there have been several notable setbacks in SLE [9], with only belimumab, a monoclonal antibody targeting the B lymphocyte stimulator (BLYS), licensed for SLE (across ages) in over 50 years [10, 11]. It has been approved for use in active adult-onset SLE patients who display serological activity (elevated anti-dsDNA titres and/or low complement levels), in light of post hoc analysis from the BLISS phase II/III trials, which showed a better response in this patient group [122, 123]. Observational studies have not demonstrated the same difference in efficacy in patients who are serologically active [124, 125].

Very recently, the first trial of intravenous belimumab in active jSLE, the PLUTO study, assessed intravenous belimumab (10 mg/kg), plus standard jSLE therapy versus...
placebo in 93 jSLE patients. At week 52, a numerically higher proportion of patients receiving belimumab met the primary endpoint of SLE Responder Index 4 (SRI4, 52.8% vs. 43.6%; OR 1.49 (95% CI 0.64 to 3.46)); however, the CI crossed 1 [126]. SRI4 is the primary outcome measure that was used in the original adult-onset SLE Belimumab trial.

The major secondary endpoint was the proportion of patients meeting the Paediatric Rheumatology International Trials Organisation/American College of Rheumatology (PRINTO/ACR) cSLE criteria for response to therapy [127]. These criteria consider the percentage change in five core components, including [1] the physician global assessment, [2] Parent Global Assessment of patient well-being, (3) the SLEDAI score, [4] the Paediatric Quality of Life inventory (PedsQL; physical-functioning domain) and [5] proteinuria. Improvement in the PRINTO/ACR jSLE criteria was measured in terms of an ACR 30 or 50 response [127]. Further major secondary endpoints included the proportion of patients with a sustained SRI4 response and parent-global assessment scores.

A significantly higher proportion of belimumab-treated patients achieved both the PRINTO/ACR 30 (52.8% vs. 27.5%; OR 2.92 (95% CI 1.19 to 7.17)) and PRINTO/ACR 50 (60.4% vs. 35.0%; OR 2.74 (95% CI 1.15 to 6.54)) responses. A sustained SRI4 response was not achieved, but there was a significant improvement in the parent-global score [126]. The present study raises important questions about the applicability of adult SLE outcome measures in jSLE, given the known differences in disease activity, severity and damage demonstrated between paediatric, adolescent and adult SLE [11, 12, 128].

In adult SLE, a phase III trial of subcutaneous belimumab versus placebo (in addition to standard SLE therapy) has been completed, meeting its primary endpoint and demonstrating that in hypocomplementemic, anti-dsDNA-positive SLE patients, weekly SC belimumab significantly improved SRI4 response, decreased severe flare incidence, and reduced corticosteroid use [129]. A paediatric specific study is required, as are further properly powered RCTs of other biologics that are under investigation in adult SLE (e.g. baricitinib, anifrolumab).

‘First do no harm’—Increasing Evidence for the Need to Steroid Sparing in jSLE Glucocorticoids remain the cornerstone of treatment in patients with active SLE and are commonly used for prolonged periods in both jSLE and adult-onset SLE, with highly variable regimens used between centres/clinicians [130]. Patients with jSLE (as opposed to adult-onset SLE) are at increased risk of steroid-related damage. In the US Lupus Outcomes Study, a longitudinal cohort of adults with confirmed SLE, jSLE patients were more likely to report steroid-related damage (OR 1.7, 95% CI 1.1–2.8) in the adjusted analysis as compared to those with adult-onset SLE [131]. As discussed above, biologic trials in SLE have by and large been disappointing as compared to other autoimmune diseases, potentially related to the complex and heterogeneous nature of SLE, and the influence of genetic, environmental and hormonal factors. Consideration of alternative endpoints for SLE clinical trials is increasingly receiving attention, with a recent meta-analysis of the steroid-sparing effects of biological treatments used in placebo-controlled, phase III RCTs, showing that most biological therapies (belimumab, tabalumab and epratuzumab) had a steroid-sparing effect, compared to placebo (pooled RR 1.36 (1.19, 1.56), leading to the suggestion that steroid dose could be included in a composite primary endpoint for SLE clinical trials [132]. Leading SLE experts have argued that problems with existing disease activity measures and treatment response outcomes may partly explain why so many trials have failed to meet their primary outcome, and have advocated for steroid reduction as a pragmatic primary outcome measure, indirectly reflecting improved disease control. A suggestion would be that the minimal clinically meaningful difference in response could become a percentage of steroid reduction (e.g. 50%, as compared to placebo) provided that the steroid reduction was sustained for a clinically relevant time period (e.g. for 6 months) [133]. The suggested doses of steroids in adult SLE treatment recommendations (intravenous, oral and tapering regimens) included in both the 2018 British Society of Rheumatology (BSR) and 2019 EULAR recommendations are lower than those advocated within some jSLE treatment regimes [134]. A specific focus on steroid sparing and monitoring of glucocorticoid toxicity in jSLE is therefore warranted.

Future Directions in the Management of jSLE and Rationale for a Treat-to-Target Approach Treatment in jSLE must aim to prevent permanent organ damage, optimise health-related quality of life (HRQOL) and ultimately improve survival through controlling disease activity, and minimising comorbidities and drug toxicity. ‘Treat to target’ (T2T), in which treatment is escalated or modified in pursuit of a pre-defined target, is part of routine clinical care in many areas of medicine (e.g. rheumatoid arthritis, hypertension, diabetes) [135]. In jSLE, a future T2T clinical trial has been advocated as an opportunity to substantially reform the clinical management of jSLE patients, using existing treatments in a more consistent and structured way, with the aim of aggressively controlling inflammation at an early stage. The TARGET LUPUS research programme (‘Targeting disease, Agreeing Recommendations and reducing Glucocorticoids through Effective Treatment in LUPUS’) has been established in order to develop a future jSLE T2T clinical trial [136, 137]. Steroid sparing and monitoring of glucocorticoid toxicity are key elements of the programme. To this end, it is important to define appropriate treatment targets and outcome measures.
specifically for use in jSLE, organ domain–driven therapeutic algorithms to be used to achieve the target and the most appropriate study design given the rarity of jSLE. A glucocorticoid toxicity index (GTI) has been developed to assess glucocorticoid-related morbidity and glucocorticoid-sparing ability of other therapies in adults with SLE [138], and a pediatric version of the GTI is eagerly awaited and should be validated in the context of jSLE.

Performance of classification criteria for SLE in jSLE

Classification criteria have been primarily developed in adult SLE populations, with the aim of defining a relatively homogeneous patient population for inclusion in clinical trials. Initial criteria were developed by The American College of Rheumatology in 1982 [139] and updated in 1997 (ACR-1997) [140]. There were concerns that the ACR criteria may miss some SLE patients, in particular those with lupus nephritis and autoantibody positivity but limited other systemic involvement. Therefore, the Systemic Lupus International Collaborating Clinics (SLICC-2012) group established criteria including 11 clinical criteria and 6 immunological criteria. They also agreed that patients with lupus nephritis and ANA or dsDNA positivity could be defined as SLE, in the absence of other clinical criteria [141]. Studies examining the performance of the SLICC criteria in international adult and jSLE cohorts have shown higher sensitivity, but lower specificity when using the SLICC versus 1997 ACR classification criteria [142–144].

The ACR and European League Against Rheumatism (EULAR) have recently collaborated to develop new classification criteria for SLE (the EULAR/ACR-2019 criteria), with validation performed in adult-onset SLE cohorts [145]. These criteria include ANA positivity as an entry criterion (ANA titre of at least 1:80 on human epithelial type 2 cells or equivalent positive test result) and use a weighted scoring system. Patients must achieve at least 10 points to be classified as having SLE. The EULAR/ACR-2019 criteria show better sensitivity and specificity compared to earlier criteria in adults with SLE [145]. Two studies have assessed the performance of the EULAR/ACR-2019 criteria in jSLE. The first study included 122 jSLE patients and 89 controls (ANA positive patients with other defined rheumatic diseases), and compared ACR-1997, SLICC-2012 and the EULAR/ACR-2019 criteria for SLE. Using a EULAR/ACR-2019 criteria cut-off score of ≥ 10, the new criteria performed less well for specificity at first visit (67.4%) as compared to both the ACR-1997 (83.2%) and SLICC-2012 criteria (80.9%). For sensitivity, the new EULAR/ACR-2019 criteria scored better than ACR 1997 (87.7% vs. 70.5%) and worse than the SLICC criteria (89.3%). An alternative cut-off point for the new EULAR/ACR-2019 criteria was proposed for use in jSLE, with a score of ≥ 13 resulting in higher specificity, positive predictive value and cut-off point accuracy [146].

The second study included 112 SLE patients aged 2–21 years (jSLE and adult SLE) and 105 controls aged 1–19 years (juvenile dermatomyositis, juvenile scleroderma or juvenile systemic sclerosis). The rheumatologist’s diagnosis of SLE served as the gold-standard criterion for identifying SLE patients. They showed the EULAR/ACR-2019 criteria to have significantly higher sensitivity (85% vs. 72%; p = 0.023) and similar specificity (83% vs. 87%; p = 0.456) than the 1997-ACR criteria. The absolute EULAR/ACR-2019 classification summary scores were higher in non-White than White cases. Sub-analysis showed that the sensitivity of the EULAR/ACR-2019 criteria was not influenced by patient ethnicity, age or gender, whereas the sensitivity of the ACR-1997 criteria was significantly higher in non-White versus White cases [147]. Further studies are warranted to assess the performance of the EULAR/ACR-2019 criteria in children, in particular as younger children with jSLE have been shown to display less ANA positivity [20].

As limited sensitivity and high specificity are wanted to homogenise patient cohorts for clinical trials, new criteria are considered a success, at least for adult-onset SLE. However, provided limited sensitivity and specificity of adult-centric criteria, it remains to be discussed whether paediatric criteria may be needed. Furthermore, it remains to be stressed that classification criteria will miss jSLE patients when used to diagnose disease (which by definition should not happen).

Conclusions

While we still do not completely understand the molecular pathophysiology of jSLE, major progress has been made over recent years. While only 1–3% of SLE patients across age groups experience disease caused by single gene mutations (monogenic SLE-like disease), this number is significantly higher in children (7–8%). In jSLE patients with ‘classic’ multifactorial disease, increased genetic burden when compared to patients with adult-onset disease contributes to early disease expression and more severe phenotypes. Lastly, epigenetic events that can be the result of environmental exposure contribute to the molecular pathophysiology and (likely) clinical phenotypes. A complete understanding of aforementioned (and potentially ‘new’) pathomechanisms will improve our understanding, and allow the development of biomarkers and individualised treatment options. Indeed, treatment is mostly empirical and based on studies in adult-onset SLE cohorts. Paediatric-specific studies are only emerging, but are key for the improvement of patient care and disease outcomes. For this, treatment targets and inclusion criteria have to be specific for children and young people and require to presence of paediatric rheumatologists in expert groups assembled e.g. by ACR and EULAR, but also industry.
Authors’ Contributions  E.M.D.S., A.C. and C.M.H. equally contributed to all stages of literature review, manuscript preparation and writing, and agreed on the final version.

Compliance with Ethical Standards

Conflict of Interest The authors report no conflict of interest relevant to this manuscript. C.M.H. was involved in scientific advisory boards for Novartis. C.M.H. received funding for a project not related to this work by Novartis. C.M.H. has received speaker honoraria from Roche and CSL Behring.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit note to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, the article does not imply that you can use it for any non-commercial use without permission. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit note to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, the article does not imply that you can use it for any non-commercial use without permission.

References

Papers of particular interest, published recently, have been highlighted as:

• Of importance

1. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62.
2. Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE) – pathophysiological concepts and treatment options. Best Pract Res Clin Rheumatol. 2017;31(4):488–504.
3. Smith EMD, Lythgoe H, Hedrich CM. Vasculitis in juvenile-onset systemic lupus erythematosus. Front Pediatr. 2019;7:149.
4. Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274.
5. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21.
6. Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayr WC, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–76.
7. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011;20(11):1187–92.
8. Huemer C, Huemer M, Dorner T, Falger J, Schacherl H, Bernecker M, et al. Incidence of pediatric rheumatic diseases in a regional population in Austria. J Rheumatol. 2001;28(9):2116–9.
9. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41.
10. Lopez P, Mozo L, Gutierrez C, Suarez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus. 2003;12(11):860–5.
11. Ambrose N, Morgan TA, Galloway J, Imonoa Y, Beresford MW, Isenberg DA, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016.
12. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwinn G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.
13. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61(1):13–20.
14. Mina R, Brunner HI. Pediatric lupus—are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin N Am. 2010;36(1):53–80.
15. Chen YM, Lin CH, Chen HH, Chang SN, Hsieh TY, Hung WT, et al. Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. Rheumatology (Oxford). 2014;53(1):180–5.
16. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonald JE, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum. 2012;64(7):2356–65.
17. Descloux E, Durieu I, Cochat P, Vital-Durand D, Ninet J, Fabien N, et al. Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford). 2009;48(7):779–84.
18. Fonseca R, Aguilar F, Rodrigues M, Brito I. Clinical phenotype and outcome in lupus according to age: a comparison between juvenile and adult onset. Reumatol Clin. 2018;14(3):160–3.
19. Hedrich CM, Zappel H, Straub S, Laass MW, Wieczorek K, Hahn G, et al. Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. Clin Rheumatol. 2011;30(2):275–83.
20. Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus. 2020;29(5):474–81.
21. Cooper GS, Parks CG, Treadwell EL, St Clair EW, Gilkeson GS, Cohen PL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus. 2002;11(3):161–7.
22. Somers EC, Thomas SL, Sneath L, Schoonen WM, Hall AJ. Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum. 2007;57(4):612–8.
23. Vilar MJ, Sato EI. Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal, Brazil). Lupus. 2002;11(8):528–32.
24. Ghaussy NO, Sibbitt W Jr, Bankhurst AD, Qualls CR. The effect of race on disease activity in systemic lupus erythematosus. J Rheumatol. 2004;31(5):915–9.
25. Hopkinson ND, Doherty M, Powell RJ. The prevalence and incidence of systemic lupus erythematosus in Nottingham, UK, 1989–1990. Br J Rheumatol. 1993;32(2):110–5.

26. Ward MM. Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. J Women's Health (Larchmt). 2004;13(6):713–8.

27. Mok CC, Lau CS. Lupus in Hong Kong Chinese. Lupus. 2003;12(9):717–22.

28. Peschken CA, Katz SJ, Silverman E, Pope JE, Fortin PR, Pineau C, et al. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. J Rheumatol. 2009;36(6):1200–8.

29. Massias JS, Smith EMD, Al-Abadi E, Armon K, Bailey K, Ciurtin C, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus. 2020;in press.

30. Crispin JC, Hedrich CM, Suarez-Fueyo A, Comte D, Tsokos GC. SLE-associated defects promote altered T cell function. Crit Rev Immunol. 2017;37(1):39–58.

31. Hedrich CM, Crispin JC, Tsokos GC. Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunify. 2014;47(4):234–41.

32. Hedrich CM, Tsokos GC. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714–24.

33. Barsalou J, Levy DM, Silverman ED. An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25(5):616–22.

34. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227–324.

35. Wu GC, Wu H, Fan LY, Pan HF. Saikosaponins: a potential treatment option for systemic lupus erythematosus. Ir J Med Sci. 2011;180(1):259–61.

36. Amano MT, Ferriani VP, Florido MP, Reis ES, Delcolli MI, Azzolini AE, et al. Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Mol Immunol. 2008;45(6):1693–702.

37. Hauck F, Lee-kirsch MA, Aust D, Roesler J, Pessler F. Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab. Arthritis Care Res. 2011;63(3):454–9.

38. Wahl R, Moe T, Shreffler D, Miller W, Atkinson JP, Schultz J, et al. C2 deficiency and a lupus erythematosus-like illness: family re-evaluation. Ann Intern Med. 1979;90(4):717–8.

39. Kemp ME, Atkinson JP, Skanes VM, Levine RP, Chaplin DD. Deletion of C4A genes in patients with systemic lupus erythematosus. Arthritis Rheum. 1987;30(9):1015–22.

40. Crispin JC, Hedrich CM, Tsokos GC. Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol. 2013;9(8):476–84.

41. Belot A, Rice GI, Omerjoe SO, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheum. 2020;2(2):e99–e109. The authors underscore the importance of monogenic defects in the pathophysiology of SLE.

42. del Rey A, Roggero E, Kabiersch A, Schafer M, Besedovsky HO. The role of noradrenergic nerves in the development of the lymphoproliferative disease in Fas-deficient, lpr/lpr mice. J Immunol. 2006;176(11):7079–86.

43. Wu J, Wilson J, He J, Xiang L, Schur PH, Moutzont JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98(5):1107–13.
60. Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M, et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum. 2007;56(12):4164–73.

61. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, et al. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2009;106(5):625–61.

62. Hammad A, Mossad YM, Nasf N, Eid R. Interferon regulatory factor 5 gene polymorphism in Egyptian children with systemic lupus erythematosus. Lupus. 2017;26(8):871–80.

63. Armstrong DL, Reiff A, Myones BL, Quismorio FP Jr, Klein-Gitelman M, McCurdy D, et al. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 2009;10(5):446–56.

64. Jakab L, Laki J, Sallai K, Temesszentandrasi G, Pozsonyi T, Kalabay L, et al. Association between early onset and organ manifestations of systemic lupus erythematosus (SLE) and a down-regulating polymorphism in the MBL2 gene. Clin Immunol. 2007;125(3):230–6.

65. Cordova EJ, Velazquez-Cruz R, Centeno F, Baca V, Orozco L. The NFR2 gene variant, −635G/a, is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus. 2010;19(10):1237–42.

66. Baca V, Velazquez-Cruz R, Salas-Martinez G, Espinosa-Rosales F, Saldana-Alvarez Y, Orozco L. Association analysis of the PTPN22 gene in childhood-onset systemic lupus erythematosus in Mexican population. Genes Immun. 2006;7(8):693–5.

67. Duffy J. Lymep disease: a clinical review. Minn Med. 1991;74(7):21–6.

68. Tirosi I, Spielman S, Barel O, Ram R, Stauber T, Pareto G, et al. Whole exome sequencing in childhood-onset lupus frequently detects single gene etiologies. Pediatr Rheumatol Online J. 2019;17(1):52.

69. Nageeb KS, Omran AA, Nageeb GS, Yousef MA, Mohammad YAA, Fawzy A. STAT4 gene polymorphism in two major autoimmune diseases (multiple sclerosis and juvenile onset systemic lupus erythematosus) and its relation to disease severity. Egypt J Neurol Psychiatr Neuropsych. 2018;54(1):16.

70. Jimenez-Morales S, Velazquez-Cruz R, Ramirez-Bello J, Bonilla-Gonzalez E, Romero-Hidalgo S, Escamilla-Guerrero G, et al. Tumor necrosis factor-alpha is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population. Hum Immunol. 2009;70(4):251–6.

71. Farid TM, Abd El Baky AM, Khalefa ES, Talatta AA, Mohamed AA, Ghiuta TA, et al. Association of tumor necrosis factor-alpha gene polymorphisms with juvenile systemic lupus erythematosus nephritis in a cohort of Egyptian patients. Iran J Kidney Dis. 2011;5(6):392–7.

72. Contreras-Cubas C, Garcia-Ortiz H, Velazquez-Cruz R, Barajas-Olmos F, Baca P, Martinez-Hernandez A, et al. Catalytically impaired TYK2 variants are protective against childhood- and adult-associated systemic lupus erythematosus in Mexicans. Sci Rep. 2019;9(1):12165.

73. Ramirez-Bello J, Jimenez-Morales S, Espinosa-Rosales F, Gomez-Vera J, Gutierrez A, Velazquez Cruz R, et al. Juvenile rheumatoid arthritis and asthma, but not childhood-onset systemic lupus erythematosus are associated with FCR3L1 polymorphisms in Mexicans. Mol Immunol. 2013;53(4):374–8.

74. Webb R, Kelly JA, Somers EC, Hughes T, Kaufman KM, Sanchez E, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis. 2011;70(1):151–6.

75. Joo YB, Lim J, Tsao BP, Nath SK, Kim K, Bae SC. Genetic variants in systemic lupus erythematosus susceptibility loci, XKR6 and GLT1D1 are associated with childhood-onset SLE in a Korean cohort. Sci Rep. 2018;8(1):9962.

76. Kisiel BM, Kosinska J, Wierzbowska M, Rutkowski-Sak L, Musiej-Nowakowsa E, Wudarski M, et al. Differential association of juvenile and adult systemic lupus erythematosus with genetic variants of oestrogen receptors alpha and beta. Lupus. 2011;20(1):85–9.

77. Lee YJ, Shin KS, Kang SW, Lee CK, Yoo B, Cha HS, et al. Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis. 2004;63(10):1244–9.

78. Salamaninejad A, Mahmoudi M, Aslani S, Pourasani S, Ziaee V, Rezaei N. Association of STAT4 gene single nucleotide polymorphisms with Iranian juvenile-onset systemic lupus erythematosus patients. Turk J Pediatr. 2017;59(2):144–9.

79. Mahmoudi M, Aslani S, Hamzeh E, Ziaee V, Pourasani S, Nicknam MH, et al. Association study of MECP2 gene single nucleotide polymorphisms in juvenile-onset systemic lupus erythematosus patients from Iran. Fetal Pediatr Pathol. 2017;36(6):423–31.

80. Velazquez-Cruz R, Orozco L, Espinosa-Rosales F, Carreno-Manjarrez R, Solis-Vallejo E, Lopez-Lara ND, et al. Association of PDCD1 polymorphisms with childhood-onset systemic lupus erythematosus. Eur J Hum Genet. 2007;15(3):336–41.

81. Chunduri NK, Storchova Z. The diverse consequences of aneuploidy. Nat Cell Biol. 2019;21(1):54–62.

82. Dillon SP, Kurien BT, Li S, Brunner GR, Kaufman KM, Harley JB, et al. Sex chromosome aneuploidies among men with systemic lupus erythematosus. J Autoimmun. 2012;38(2–3):129–34.

83. Margery-Muir AA, Bundell C, Nelson D, Groth DM, Wetherall JD. Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev. 2017;16(3):258–68.

84. Scofield RH, Brunner GR, Namjou B, Kimberly RP, Ramsey-Goldman R, Petri M, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58(8):2511–7.

85. Liu K, Kurien BT, Zimmerman SL, Kaufman KM, Taft DH, Kottyan LC, et al. X Chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47,XXY in systemic lupus erythematosus and Sjogren’s syndrome. Arthritis Rheum. 2016;68(5):1290–300.

86. Webb K, Peckham H, Radziszewska A, Menon M, Oliveri P, Simpson F, et al. Sex and pubertal differences in the type 1 interferon pathway associate with both X chromosome number and serum sex hormone concentration. Front Immunol. 2018;9:3167.

87. Zhang H, Kooboth M, Lee P, Rice A, Driscoll DJ, Zori R, et al. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p. Arthritis Rheum. 2006;54(5):1573–9.

88. Fremond ML, Gitaux C, Bonnet D, Guiddir T, Crow YJ, de Pontual L, et al. Mosaic tetrasomy 9p: a Mendelian condition associated with pediatric-onset overlap myositis. Pediatrics. 2015;136(2):e544–7.

89. Li YR, Glessner JT, Coe BP, Li J, Mohebnasab M, Chang X, et al. Rare copy number variants in over 100,000 European ancestry subjects reveal multiple disease associations. Nat Commun. 2020;11(1):255.

90. Pereira KM, Faria AG, Liphhaus BL, Jesus AA, Silva CA, Carneiro-Sampaio M, et al. Low C4, C4A and C4B gene copy numbers are stronger risk factors for juvenile-onset than for adult-onset systemic lupus erythematosus. Rheumatology (Oxford). 2016;55(5):869–73.
91. Garcia-Ortiz H, Velazquez-Cruz R, Espinosa-Rosales F, Jimenez-Morales S, Baca V, Orozco L. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis. 2010;69(10):1861–5.

92. Barbosa FB, Simioni M, Wielicz CEV, Torres FR, Molck MC, Bonilla MM, et al. Copy number variation in the susceptibility to systemic lupus erythematosus. PLoS One. 2018;13(11):e0206683.

93. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153(1):38–55.

94. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013;14(3):204–20.

95. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol. 2005;174(10):6212–9.

96. Oelke K, Lu Q, Richardson D, Wu A, Deng C, Hanash S, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 2004;50(6):1850–60.

97. Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4(+) T cells of systemic lupus erythematosus. J Autoimmun. 2013;41:92–9.

98. Hedrich CM. Mechanistic aspects of epigenetic dysregulation in SLE. Clin Immunol. 2018;196:3–11.

99. Keshavarz-Fathi M, Sanati G, Sadr M, Mohhebbi B, Ziaee V, Rezaei N. DNA methylation of CD70 promoter in juvenile systemic lupus erythematosus. Fetal Pediatr Pathol. 2020:1–10.

100. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.

101. Huang X, Su G, Wang Z, Shangguan S, Cui X, Zhu J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.

102. Hofmann SR, Mabert K, Kapplusch F, Russ S, Northey S, Beresford MW, et al. cAMP response element modulator alpha induces dual specificity protein phosphatase 4 to promote effector T cells in juvenile-onset lupus. J Immunol. 2019;203(11):2807–16.

The authors link increased expression of the transcription factor CREM alpha with epigenetic alterations in CD4+ T cells from jSLE patients and imbalanced cytokine expression.

103. Hedrich CM, Crispin JC, Rauen T, Ioannidis C, Apostolidis SA, Lo MS, et al. cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proc Natl Acad Sci U S A. 2012;109(41):16606–11.

104. Hedrich CM, Mabert K, Rauen T, Tsokos GC. DNA methylation in systemic lupus erythematosus. Epigenomics. 2017;9(4):505–25.

105. Hedrich CM, Rauen T, Tsokos GC. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem. 2011;286(50):43429–36.

106. Rauen T, Hedrich CM, Tenbrock K, Tsokos GC. cAMP responsive element modulator: a critical regulator of cytokine production. Trends Mol Med. 2013;19(4):262–9.

107. Charras A, Hedrich CM. The role of epigenetics in paediatric rheumatic disease. Curr Opin Rheumatol. 2019;31(5):450–63.

108. Zheng C, Hayes JJ. Structures and interactions of the core histone tail domains. Biopolymers. 2003;68(4):539–46.

109. Shu J, Li L, Zhou LB, Qian J, Fan ZD, Zhuang LL, et al. IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors. Oncotarget. 2017;8(29):47184–94.

110. Koga T, Hedrich CM, Mizui M, Yoshida N, Otomo K, Lieberman LA, et al. CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J Clin Invest. 2014;124(5):2234–45.

111. Rauen T, Hedrich CM, Juan YT, Tenbrock K, Tsokos GC. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem. 2011;286(50):43437–46.

112. Rauen T, Juan YT, Hedrich CM, Kiso-Toh K, Tsokos GC. A novel isofrom of the orphan receptor RORgamma suppresses IL-17 production in human T cells. Genes Immun. 2012;13(4):346–50.

113. Lu J, Clark AG. Impact of microRNA regulation on variation in human gene expression. Genome Res. 2012;22(7):1243–54.

114. Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897–901.

115. Apostolidis SA, Rauen T, Hedrich CM, Crispin JC. Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J Biol Chem. 2013;288(37):26775–84.

116. Apostolidis SA, Rodriguez-Rodriguez N, Suarez-Fuego A, Dioufa N, Ozcan E, Crispin JC, et al. Phosphatase PP2A is required for the function of regulatory T cells. Nat Immunol. 2016;17(5):556–64.

117. Crispin JC. Apostolidis SA, Finnell MJ, Tsokos GC. Induction of PP2A Bbeta, a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2011;108(30):12443–8.

118. Crispin JC, Apostolidis SA, Rosetti F, Keszei M, Wang N, Terhorst C, et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmunity disease through an IL-17-dependent mechanism. J Immunol. 2012;188(8):3557–71.

119. Katsiari CG, Kyttaris VC, Juan YT, Tsokos GC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest. 2005;115(11):3193–204.

120. Sunahori K, Nagpal K, Hedrich CM, Mizui M, Fitzgerald LM, Tsokos GC. The catalytic subunit of protein phosphatase 2A (PP2Ac) promotes DNA hypomethylation by suppressing the phosphorylated mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase (MEK)/phosphorylated ERK/DNMT1 protein pathway in T-cells from controls and systemic lupus erythematosus patients. J Biol Chem. 2013;288(30):21936–44.

121. Lashine YA, Salah S, Aboelenein HR, Abdelaziz AI. Correcting the expression of miRNA-155 represses PP2Ac and enhances the release of IL-2 in PBMCs of juvenile SLE patients. Lupus. 2015;24(3):240–7.

122. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9.

123. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol. 2012;188(8):3557–71.

124. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. Cutting edge: protein phosphatase 2A confers susceptibility to autoimmune disease through an IL-17-dependent mechanism. J Immunol. 2012;188(8):3557–71.
125. Ruperto N, Ravelli A, Oliveira S, Alessio M, Mihaylova D, Pasic
126. Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy
127. Changing paradigms in the treatment of systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum. 2006;55(3):355–63.
128. Brunner HI, Gladman DD, Ibanez D, Urowitz MD, Silverman ED.
129. Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van
130. Brunner HI, Klein-Gitelman MS, Ying J, Tucker LB, Silverman
131. Heshin-Bekenstein M, Trupin L, Yelin E, von Scheven E,
132. Oon S, Huq M, Godfrey T, Nikpour M. Systematic review, and
133. Houssiau FA. Time to change the primary outcome of lupus trials. Arthritis Rheum. 2008;58(2):556–62.
134. Mina R, von Scheven E, Ardoin SP, Eberhard BA, Punaro M,
135. Smith EMD, Gorst S, Beresford MW, Birks Y. It gives the treat-
136. Smith EMD, Thamaratnam K, Jorgensen AL, Beresford MW.
137. Smith EMD, Thamaratnam K, Jorgensen AL, Beresford MW.
138. Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES,
139. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield
140. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
141. Petrini M, Orba AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR,
142. Ines L, Silva C, Galindo M, Lopez-Longo FJ, Terroso G, Romao VC, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res. 2015;67(8):1180–5.
143. Lythgoe H, Morgan T, Heaf E, Lloyd O, Al-Abadi E, Armon K, et al. Evaluation of the ACR and SLICC classification criteria in juvenile-onset systemic lupus erythematosus: a longitudinal analysis. Lupus. 2017;26(12):1285–90.
144. Hag E, Taggartione A, Batu ED, Ravelli A, Khalil SM, Marks SD, et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol. 2014;32(3):440–4.
145. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9.
146. Rodrigues Fonseca A, Felix Rodrigues MC, Sztajnbok FR, Gerardin Poirot Land M, de Oliveira Knupp Feitosa S. Comparison among ACR1997, SLICC and the new EULAR/ ACR classification criteria in childhood-onset systemic lupus erythematosus. Adv Rheumatol. 2019;59(1):20.
147. Aljaberi N, Nguyen K, Strahle C, Merritt A, Mathur A, Brunner HI. The performance of the new 2019-EULAR/ACR classification criteria for systemic lupus erythematosus in children and young adults. Arthritis Care Res (Hoboken) 2020.